(CercleFinance.com) – Valneva shares ended the day up nearly 3%, benefiting from the positive analysis by Oddo BHF.
In a note on European biotechnology stocks, Oddo BHF indicates that it favors Valneva, as well as Abivax and Genfit, with ‘outperformance’ opinions and price targets raised to 12, 30 and 8.8 euros respectively.
“These three titles benefit from solid shareholders accompanied by a clinical and regulatory newsflow whose risk/reward seems attractive to us over the next 18 months,” explains the analyst in charge of the file.
Oddo BHF points out that the stock market performance of the sector at the start of 2023 was once again extremely heterogeneous. “A rebound in M&A operations is finally materializing, which should reinvigorate an apathetic sector,” he points out, however.